Anaplastic Astrocytoma Global Market Report 2024

The global anaplastic astrocytoma market has grown strongly in recent years. It will grow from $6.27 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to growing adoption of targeted therapies, patient advocacy and awareness, clinical trial expansion, healthcare policy and funding, government initiatives.

The global anaplastic astrocytoma market is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing research and development activities, growing demand for personalized medicine, growing investments, increasing awareness of the disease, increasing stress and depression. Major trends in the forecast period include advancements in neurosurgery, radiation therapy advancements, clinical trials and research, adoption of telemedicine and remote monitoring technologies, advancements in imaging, biotechnology and drug development.

The anaplastic astrocytoma market is anticipated to experience growth due to the increasing occurrence of both primary malignant and non-malignant brain tumors. Brain tumors are abnormal growths within the brain that can be categorized as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying levels of aggressiveness and potential to spread. Anaplastic astrocytoma treatment involves the removal of the tumor and surrounding affected tissue while preserving brain function. For instance, as reported by the American Society of Clinical Oncology (ASCO), a non-profit organization based in the United States, it is estimated that around 24,810 adults in the U.S. will receive diagnoses of primary cancerous brain and spinal cord tumors in March 2023, with 14,280 cases in men and 10,530 in women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors is poised to be a driving factor for the growth of the anaplastic astrocytoma market in the future.

The anticipated growth in the anaplastic astrocytoma market is expected to be driven by government funding for brain cancer research. Government funding involves financial support provided by government entities at various levels (federal, state, or local) to support organizations, initiatives, projects, programs, or individuals. Numerous government authorities are actively funding research related to brain cancer treatments, including anaplastic astrocytoma. For example, in June 2023, the Australian Department of Health and Aged Care initiated The Australian Brain Cancer Mission, allocating $136.66 million to support brain cancer research. The mission aims to double survival rates and enhance the quality of life for brain cancer patients, including those with anaplastic astrocytoma. As a result, government funding for brain cancer research is a key driver for the anaplastic astrocytoma market.

A significant challenge in the market's growth during the forecast period is the poor prognosis associated with anaplastic astrocytoma. Poor prognosis is characterized by factors that indicate an unfavorable outcome or a lower likelihood of recovery for individuals with this specific disease. Prognosis remains unfavorable for many astrocytoma types and other brain tumors, prompting numerous patients with anaplastic astrocytoma to participate in clinical trials. For example, as of July 2023, poor prognosis is often linked to the absence of EGFR, with unfavorable prognostic factors including age over 40 years, tumor size exceeding 6 cm, tumor crossing the midline, and the presence of neurological deficits before surgical resection. Elevated Kallikrein levels associated with patient prognosis, such as increased KLK6 / KLK7-IR, are correlated with poor outcomes, while immunoreactivity with KLK6/9 is linked to decreased survival rates. Consequently, the existence of poor prognoses presents a significant impediment to the growth of the anaplastic astrocytoma market in the forecast period.

Prominent companies in the anaplastic astrocytoma market are actively engaged in pioneering novel treatment options with the aim of enhancing effectiveness, reducing side effects, and ultimately improving patient outcomes. For example, in June 2022, the U.S. Food and Drug Administration, a federal agency based in the United States, granted accelerated approval for an innovative treatment combination featuring the oral medications dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors characterized by the BRAF V600E mutation. This approval applies to both adult and pediatric patients with high- and low-grade gliomas that have shown progression following prior treatments. The BRAF V600E mutation is prevalent in various types of gliomas, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas. The decision to grant approval was based on clinical trials of the Tafinlar-Mekinist combination therapy, which demonstrated tumor shrinkage benefits for both adult and pediatric glioma patients. High-grade glioma patients exhibited a 33% response rate, low-grade glioma patients showed a 50% response rate, and pediatric glioma patients demonstrated a 25% response rate.

In November 2021, Merck & Co. Inc., a pharmaceutical company headquartered in the United States, completed the acquisition of Acceleron Pharma Inc. for a total of $11.5 billion. This strategic acquisition allowed Merck to broaden its portfolio in the rare disease sector and gain access to cutting-edge research in the development of new therapeutics. It aligns with Merck's commitment to addressing critical health needs and enhances its overall business development strategy. Acceleron Pharma Inc. is a biotechnology company based in the United States, specializing in the development of treatments for anaplastic astrocytoma.

Major players in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma's Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.

North America was the largest region in the anaplastic astrocytoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anaplastic astrocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anaplastic astrocytoma is categorized into four main grades such as Grade I, Grade II, Grade III, and Grade IV. Grade I anaplastic astrocytoma tumors are the least aggressive and considered benign. They are typically treated with surgical excision, routine monitoring, and follow-up procedures. Treatment options for anaplastic astrocytoma also include surgery, chemotherapy, and radiation, which are further classified into pre-registration and clinical trial phases. These treatments are administered by medical facilities such as hospitals and clinics, and the medications can be obtained from retail pharmacies and online pharmacies.

This report provides anaplastic astrocytoma market statistics, including anaplastic astrocytoma industry global market size, regional shares, competitors with an anaplastic astrocytoma market share, detailed anaplastic astrocytoma market segments, market trends and opportunities and any further data you may need to thrive in the anaplastic astrocytoma industry. This anaplastic astrocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaplastic astrocytoma market consists of revenues earned by entities by providing targeted therapies, genetic testing and biomarker analysis, clinical trials and healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anaplastic astrocytoma market also includes sales of surgical equipment, imaging devices and radiation therapy equipment that are used in providing anaplastic astrocytoma treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.